Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...

Topline results expected to be released in August 2025Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc.

CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...

Detailed price information for Spectral Medical Inc (EDT-T) from The Globe and Mail including charting and trades.

This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company ... is a significant step in our journey toward FDA ...

This follows the March 27 announcement of the product launch and represents a key milestone ... (FDA) has designated YUFLYMA® (adalimumab-aaty), as an interchangeable biosimilar to Humira® (adalimumab ...

TD Cowen also suspended the price target for Milestone Pharmaceuticals, citing uncertainties surrounding the regulatory approval and commercial launch timing of etripamil. The analysts expressed ...

Challenges include potential delays in site activation and patient enrollment despite FDA-approved protocol changes. Analysts raised concerns about achieving enrollment milestones tied to funding ...

In connection with the acquisition, the combined company adopted the name Opus Genetics, Inc., and began trading on Nasdaq under the ticker symbol ... in part from a milestone payment of $10.0 million ...

Milestone, which was seeking FDA approval of etripamil for the conversion of acute episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults, said the agency raised two issues ...

Investing.com -- Milestone Pharmaceuticals Inc . (NASDAQ:MIST) shares plummeted 60% following a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its New Drug ...